About Adcendo

Adcendo ApS is a clinical-stage biotech company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts.

The company is developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need using a target- and indication-driven approach to develop therapies with the potential for an optimal balance of efficacy and tolerability. Led by a team of experienced biopharma executives with a track record of advancing multiple ADCs to approval, Adcendo integrates deep insights into target and disease biology, with research, clinical development and commercial expertise to drive next-generation cancer therapies.

Adcendo is currently advancing three ADCs in the clinic:

1) ADCE-T02 targeting Tissue Factor, which is overexpressed in a broad range of solid tumors, including head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma;

1. 2) ADCE-D01 targeting uPARAP, which is overexpressed in soft tissue sarcoma and other cancers of mesenchymal origin; and

1. 3) ADCE-B05, for which the target is undisclosed, is currently being evaluated in squamous cell tumors.